title: Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.
abstract: OBJECTIVE
  To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Three hundred twenty patients with Stage III (A+B) or IV NSCLC were enrolled. A Platinum-based chemotherapy was given to each subjects and therapeutic effect was evaluated. The two galectin-3 genetic polymorphisms, namely, galectin-3 +191 A>C and +292 A>C, were genotyped.
  
  
  RESULTS
  The polymorphic genotypes and the allele frequency of galectin-3 +191 A>C were not significantly different between responders and non-responders to chemotherapy. For galectin-3 +292 A>C, the AA genotype and A allele distribution were significantly higher in responders than in non-responders. Logistic regression analysis showed CC genotype of galectin-3 +292 presented higher risk of being non-responders compared with the AA genotype (OR = 2.96, 95 % CI: 1.55-5.47; P < 0.001). The overall survival in patients with AA genotype of galectin-3 +292 were significantly longer than in those with CC genotype (25.6 vs. 19.5 months, P = 0.013). The hazard ratio for CC genotype of galectin-3 +292 was 2.43 (95 % CI: 2.03-3.98, compared with AA carriers, P = 0.003).
  
  
  CONCLUSIONS
  The galectin-3 genetic polymorphisms of galectin-3 +292, rather than galectin-3 +191, were associated with the chemotherapy response and prognosis of NSCLC.
authors.affiliation: Department of oncology, First People Hospital of Lianyungang, Lianyungang, Jiangsu province, 222002, China.
authors.forename: Fenglei
authors.initials: F
authors.lastname: Wu
authors.forename: Nan
authors.initials: N
authors.lastname: Hu
authors.forename: Yu
authors.initials: Y
authors.lastname: Li
authors.forename: Baoxiang
authors.initials: B
authors.lastname: Bian
authors.forename: Guanghui
authors.initials: G
authors.lastname: Xu
authors.forename: Yitong
authors.initials: Y
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D037502:Galectin 3 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis
chemical_list: D037502:Galectin 3; D010984:Platinum